⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 21, 2002Cochrane libraryOpen Access

Chelation therapy for atherosclerotic cardiovascular disease

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does EDTA chelation therapy improve clinical outcomes in patients with atherosclerotic cardiovascular disease?

Population

5 RCTs including 260 patients with atherosclerotic cardiovascular disease

Comparison

Ethylene diamine tetraacetic acid chelation… vs Placebo or no treatment

Design

Systematic_review

Authors

ADAntonio L Dans FTFlordeliza N Tan

Discussion

Loading...

Member takes

Implication

EDTA chelation shows no surrogate benefit in small trials; leaves open effects on mortality and events.

Structured PICO

Does EDTA chelation therapy improve clinical outcomes in patients with atherosclerotic cardiovascular disease?

P

Population

5 RCTs including 260 patients with atherosclerotic cardiovascular disease

I

Intervention

Ethylene diamine tetraacetic acid (EDTA) chelation therapy

C

Comparator

Placebo or no treatment

O

Outcome

Total or cause-specific mortality, non-fatal cardiovascular events, direct or indirect measurement of disease severity, subjective measures of improvement or adverse events

There is currently insufficient evidence from randomized controlled trials to determine the effectiveness of EDTA chelation therapy for improving clinical outcomes in atherosclerotic cardiovascular disease.

Limitations

Mortality and non-fatal events not reported in any study
Insufficient evidence
One study interrupted prematurely with unavailable data

Cite This Study

Dans et al. (2002) studied this question.

synapsesocial.com/papers/6a7ccea8eadc8c84e2165048 https://doi.org/10.1002/14651858.cd002785

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

1Current and Future Drug Therapies for Claudication1997 · 38 citations